Lancet NAD+ Blood Level Study: Key Findings Explained in Plain Language
Direct NAD+ supplementation increased blood NAD+ levels 2.6-3.1x within weeks, far exceeding typical results from oral precursors like NMN or NR.
Study overview
Conducted by
Multi-center research group
Patients
Healthy adults in a dose-ranging study
Duration
Weeks (acute dosing phase with follow-up)
Published in
The Lancet eClinicalMedicine
Year
2023
Key findings
Blood NAD+ increased 2.6-3.1x from baseline
Depending on dose, participants achieved a 160-210% increase in circulating NAD+ levels. These increases were measured by validated blood assays and were consistent across participants.
Response was dose-dependent
Higher doses produced greater NAD+ elevation, confirming a clear pharmacological dose-response relationship. This is important because it demonstrates a predictable, controllable effect.
Increases occurred within weeks, not months
Unlike lifestyle interventions or oral precursors that may take months to show measurable NAD+ changes, direct supplementation reached target levels rapidly.
Well-tolerated across dose ranges
No serious adverse events were reported. Mild flushing was the most common side effect, consistent with rapid NAD+ elevation.
What this means for you
This study answers the fundamental question about NAD+ supplementation: does it actually raise levels? Yes -- by 2.6 to 3.1 times baseline. Oral NMN and NR rarely produce comparable increases because of the conversion steps and absorption losses. Direct NAD+ supplementation is the most efficient path to meaningful blood level elevation.
Limitations
The study measured blood NAD+ levels, not tissue-specific levels (brain, muscle, etc.). Duration was relatively short; long-term maintenance studies are needed. Clinical outcome correlations (energy, cognition) were not the primary endpoint. Cost comparison with oral alternatives was not addressed.
See if this compound is right for your goals
Take a 2-minute quiz. Get a personalized protocol.